Non-catechol-based high-affinity selective dopamine D receptor (D1R) agonists were recently described, and candidate PET ligands were selected on the basis of favorable properties. The objective of this study was to characterize in vivo in nonhuman primates 2 novel D1R agonist PET radiotracers, racemic F-MNI-800 and its more active atropisomeric (-)-enantiomer, F-MNI-968. Ten brain PET experiments were conducted with F-MNI-800 on 2 adult rhesus macaques and 2 adult cynomolgus macaques, and 8 brain PET experiments were conducted with F-MNI-968 on 2 adult rhesus macaques and 2 adult cynomolgus macaques. PET data were analyzed with both plasma-input-based methods and reference-region-based methods. Whole-body PET images were acquired with F-MNI-800 from 2 adult rhesus macaques for radiation dosimetry estimates. F-MNI-800 and F-MNI-968 exhibited regional uptake consistent with D1R distribution. Specificity and selectivity were demonstrated by dose-dependent blocking with the D antagonist SCH-23390. F-MNI-968 showed a 30% higher specific signal than F-MNI-800, with a nondisplaceable binding potential of approximately 0.3 in the cortex and approximately 1.1 in the striatum. Dosimetry radiation exposure was favorable, with an effective dose of about 0.023 mSv/MBq. F-MNI-968 has significant potential as a D1R agonist PET radiotracer, and further characterization in human subjects is warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882897 | PMC |
| http://dx.doi.org/10.2967/jnumed.120.256008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Activation of brown and beige fat biogenesis promotes metabolic health in rodents and humans, but typically requires cold exposure or pharmacological activation of β-adrenergic receptors, which may pose cardiovascular risks. Dietary intervention represents a clinically viable alternative strategy to induce beige cells and thus enhance metabolic health, though the underlying mechanisms remain poorly understood. In this study, we identified specific microbiota members in both mice and humans that promote browning of white adipose tissue (WAT) and ameliorate metabolic disorders in the context of a low-protein diet (LPD).
View Article and Find Full Text PDFGLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.
Otol Neurotol
January 2025
Cedars-Sinai Medical Center, Division of Otolaryngology-Head and Neck Surgery, Los Angeles, CA.
Introduction: GLP-1 receptor agonists (GLP-1 RAs) have gained traction in the management of obesity. There is limited literature on the implications of GLP-1 RAs in the field of otolaryngology.
Methods: We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Consistent evidence that brain serotonin 2A receptor binding is positively associated with personality-based risk markers of depression.
Br J Psychiatry
December 2024
Neurobiology Research Unit, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Background: Using [F]altanserin, a serotonin 2A receptor (5-HTR) antagonist Positron Emission Tomography (PET) tracer, a positive association between cortical 5-HTR binding and the inward-directed facets of neuroticism has been demonstrated in healthy individuals. Psilocybin, a 5-HTR agonist, shows promise for the treatment of depression, reducing neuroticism and mood symptoms potentially via hypothalamic-pituitary-adrenal (HPA) modulation. 5-HTR and neuroticism are both modulated by HPA axis function.
View Article and Find Full Text PDFPET imaging of GABA receptors in pancreatic islets by [C]flumazenil.
EJNMMI Res
December 2024
Department of Medical Cell Biology, Department of Medical Sciences, Science for Life Laboratory, Uppsala University, Box 571, 75123, Uppsala, Sweden.
Background: Type 1 diabetes (T1D) is an autoimmune disease characterized by a progressive β-cell destruction. There are no clinically established methods for quantifying endocrine cells of the pancreas and current knowledge is almost exclusively based on autopsy material and functional measurements. Based on the expression of the γ-aminobutyric acid A receptors (GABARs) in pancreatic islets and the fact that GABAR agonists are being explored as treatment for T1D, we hypothesized that the positron emission tomography (PET) tracer [C]flumazenil ([C]FMZ) could serve as a marker of the endocrine mass of the pancreas.
View Article and Find Full Text PDFNeurochemical characterization of 5-HTR partial agonists with simultaneous PET-MRI.
J Cereb Blood Flow Metab
November 2024
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, USA.
Article Synopsis
- This study investigates the effects of different serotonin 2A receptor (5-HTR) agonists, such as psilocybin, lisuride, and 25CN-NBOH, to understand their potential in psychedelic drug applications.
- Using advanced imaging techniques like PET and phMRI on nonhuman primates, the researchers evaluated how these agonists affect brain blood flow and receptor occupancy.
- Findings suggest that mixed agonists like psilocybin and lisuride create complex blood volume responses while 25CN-NBOH leads to simpler responses, shedding light on how these drugs could be used to treat psychiatric disorders.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!